788 related articles for article (PubMed ID: 27756212)
1. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
[TBL] [Abstract][Full Text] [Related]
2. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
3. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cross-reactivity between flaviviruses with sera of patients with Japanese encephalitis showed the importance of neutralization tests for the diagnosis of Japanese encephalitis.
Maeki T; Tajima S; Ikeda M; Kato F; Taniguchi S; Nakayama E; Takasaki T; Lim CK; Saijo M
J Infect Chemother; 2019 Oct; 25(10):786-790. PubMed ID: 31105002
[TBL] [Abstract][Full Text] [Related]
5. Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?
Turtle L; Brindle HE; Schluter WW; Faragher B; Rayamajhi A; Bohara R; Gurung S; Shakya G; Yoksan S; Dixit S; Rajbhandari R; Paudel B; Adhikari S; Solomon T; Griffiths MJ
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007269. PubMed ID: 30986252
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.
Ly MHP; Moi ML; Vu TBH; Tun MMN; Saunders T; Nguyen CN; Nguyen AKT; Nguyen HM; Dao TH; Pham DQ; Nguyen TTT; Le TQM; Hasebe F; Morita K
BMC Infect Dis; 2018 Jan; 18(1):31. PubMed ID: 29321001
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
[TBL] [Abstract][Full Text] [Related]
9. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
[TBL] [Abstract][Full Text] [Related]
10. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
[TBL] [Abstract][Full Text] [Related]
11. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.
Gao N; Li J; Sheng Z; Chen H; Fan D; Wang P; An J
Appl Microbiol Biotechnol; 2019 Jun; 103(12):4977-4986. PubMed ID: 31037380
[TBL] [Abstract][Full Text] [Related]
12. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of an assay for detection of Japanese encephalitis virus specific antibody responses.
Pushpakumara PD; Jeewandara C; Gomes L; Perera Y; Wijewickrama A; Malavige GN; Goonesekara C
PLoS One; 2020; 15(10):e0238609. PubMed ID: 33112881
[TBL] [Abstract][Full Text] [Related]
14. Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination.
Shu PY; Chen LK; Chang SF; Yueh YY; Chow L; Chien LJ; Chin C; Lin TH; Huang JH
Vaccine; 2001 Feb; 19(13-14):1753-63. PubMed ID: 11166901
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the protective ability of plasma from Japanese individuals against mosquito-borne viral infections.
Shinohara N; Owada T; Matsumoto C; Uchida S; Nagai T; Satake M; Tadokoro K
Trans R Soc Trop Med Hyg; 2017 Sep; 111(9):393-401. PubMed ID: 29294131
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
17. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
19. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
20. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus.
Ito M; Mukai RZ; Takasaki T; Kotaki A; Kurane I
Arch Virol; 2010 Oct; 155(10):1617-24. PubMed ID: 20644969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
